2020 marks an important year in the evolution of BioTM. We received our first impact factor of 6.091 this year. This is a massive accomplishment for all stakeholders of the journal. The journal was formally launched in 2015 and we published our first issue in 2016. Within a short period of 4 years, we were able to reach this significant milestone.

Huge thanks to all BioTM authors who trusted the journal with their precious manuscripts in the early, unproven days. Submission of high‐quality manuscripts is the principal reason that led to an impressive launching impact factor. BioTM welcomes manuscripts in all aspects of bioengineering including drug delivery, drug discovery and development, tissue engineering, synthetic biology, biosensors, organoids and organ‐mimetic systems, stem cell therapies, gene therapies, immunotherapies, patient‐targeted therapies, medical devices, regenerative medicine, implant/patient interface, computational modeling, and bioinformatics.

Areas including drug delivery, gene therapy, sirRNA delivery, regenerative medicine, nanomedicine, biomedical devices, and cell therapy have been particularly well represented in the manuscripts recently submitted to BioTM. This is expected because these fields represent some of the most active research areas at the interface of medicine and engineering, especially those that focus on developing/testing novel materials or devices, for example, nanoparticles and microneedles for drug delivery. Indeed, some of the recent BioTM papers in drug delivery have focused on the use of microneedles for vaccine delivery.1-3 These papers demonstrated novel microneedle designs, for example, self‐healing microneedles for encapsulation, as well as translational studies to nonhuman primate studies for hepatitis B vaccine. Along the same general theme, studies on ocular drug delivery devices were also featured prominently.4, 5 The studies described novel designs of protein‐delivery systems as well as studies in nonhuman primates demonstrating long‐lasting release of proteins in the eye. Collectively, the reports along the translational axis of drug delivery devices represent a growing need in the field, and we are delighted to see those represent in our issues. On a more fundamental side, microfluidic devices leading to model systems for blood–brain barrier were also described.6 Such devices are playing an increasing role in in vitro optimization and acceleration of drug development timescales.

Tissue engineering was also a commonly discussed subject in recent BioTM papers, also consistent with the large community of researchers working at the interface of engineering and regenerative medicine. Covered tissue engineering topics included engineering of hydrogel and decellularized matrices and generation of tissue‐specific blood vessels.7-9 Polymeric materials of various forms were discussed, including composite materials, hydrogels, and capsules.10-12 These reports represent the great activity of research focused on understanding the design features of polymeric materials, polymer‐tissue interface, as well as in vivo assessment of their biological functions.

Consistent with general literature trends, a significant number of recent papers were focused on nanomedicine. Topics included translatable mouse models for cancer,13 new designs of nanoparticles,14, 15 and scalable synthesis methods for nanoparticles.16, 17 Translationally focused reports, for example, novel tumor models for nanomedicine and scalable synthesis methods, represent a particular need of time and we look forward to receiving more similar translationally focused nanomedicine manuscripts in future. Studies demonstrating novel applications of nanoparticles were also featured prominently in our recent publications, including the use of nanoparticles for improved residence of sunscreens on the skin18 and siRNA delivery for applications in lymphoma and wound healing.19, 20 Papers on medical devices included control algorithms for artificial pancreas.21 Along with original research articles, we also published reviews on some of the active current topics in translational medicine including ionic liquids for biomedical applications,22 clinical landscape of nanomedicine,23 and translational status of nanocrystals.24 Reviews in BioTM are particularly focused on reporting translational advances and hurdles in the field.

We are thankful for the strong support from our editorial board members. In 2020, we added six new editorial board members: Jennifer West (Duke, University), Xiaoyuan Chen (NIH), David Mooney (Harvard University), Molly Stevens (Imperial College, London), Maria Jose Alonso (University of Santiago de Compostela, Spain), and Andreas Lendlein (Helmholtz Institute of Biomaterial Science, Germany). We look to our board for guidance and vision. We are especially thankful to the board members for routinely publishing their own research in BioTM. We feature one board member in each issue. You can read these biographies at https://aiche.onlinelibrary.wiley.com/journal/hub/journal/23806761/homepage/editorialboardprofiles.html.

We are pleased with the enthusiastic participation of the young generation of researchers in the launch and growth of BioTM. The support came in various forms including guest editing of special issues, submission of manuscripts, and reviewing manuscripts. Our special thanks to Prof. Aaron Anselmo of University of North Carolina, Chapel Hill, who started our feature BioTM Buzz, which highlights select papers from each issue. Follow BioTM_Buzz on Twitter for updates on our publications.

BioTM has published several special issues dedicated to several topics, including nanoparticles in medicine, nucleic acid delivery, responsive materials, and bioengineered therapeutics as well as special issues dedicated to conferences in bioengineering and translational medicine and Engineering Conferences International (ECI) nanotechnology in medicine. We also published a special issue honoring two luminaries of the field: Robert Langer and Nicholas Peppas. These special issues were edited by our enthusiastic patrons, including Profs. Kaushal Rege, Kannan Rangaramajunam, Paolo Decuzzi, Zhen Gu, Kathryn Whitehead, Pankaj Karande, Josue Snitzman, and Millicent Sullivan. We are deeply thankful for their dedication. Without the enthusiastic participation of these committed individuals, we would not have gotten off to such a great start. We also thank Arthur Baulch for excellent management of the operation, Cynthia Mascone for leadership in publication policies, and the entire Wiley team for publication strategies.

Having finished the 5‐year journey, I look forward to the next phase of the journal, which will include an increase in the number of publications each year, expansion of covered topics, and increased representation of industry and international authors in the journal. Thank you all for your strong support to the journal and look forward to your continued support in coming years.

2020年是BioTM演进的重要一年。今年，我们收到了第一个影响因子6.091。对于期刊的所有利益相关者而言，这都是巨大的成就。该杂志于2015年正式发行，我们于2016年出版了第一期。在短短的4年内，我们能够实现这一重要里程碑。

非常感谢所有BioTM作者，他们在未经证实的早期就以其宝贵的手稿信任了该期刊。提交高质量手稿是导致令人印象深刻的启动影响因素的主要原因。BioTM欢迎生物工程各个方面的手稿，包括药物输送，药物发现和开发，组织工程，合成生物学，生物传感器，类器官和器官模拟系统，干细胞疗法，基因疗法，免疫疗法，针对患者的疗法，医疗器械，再生疗法医学，植入物/患者界面，计算模型和生物信息学。

在最近提交给BioTM的手稿中，包括药物输送，基因治疗，sirRNA输送，再生医学，纳米医学，生物医学设备和细胞治疗的领域尤其突出。这是可以预期的，因为这些领域代表了医学和工程学界最活跃的研究领域，尤其是那些专注于开发/测试新型材料或装置的领域，例如用于药物输送的纳米颗粒和微针。的确，最近有关药物输送的BioTM论文集中在使用微针进行疫苗输送方面。1-3这些论文展示了新颖的微针设计，例如用于封装的自修复微针，以及针对乙型肝炎疫苗的非人类灵长类动物研究的转化研究。沿着相同的总体主题，有关眼部药物输送装置的研究也很突出。4，5这些研究描述了蛋白质递送系统的新颖设计以及在非人类灵长类动物中的研究，这些研究证明了蛋白质在眼睛中的持久释放。总的来说，沿着药物输送装置的平移轴的报告代表了该领域不断增长的需求，我们很高兴看到这些代表了我们的问题。从更基本的方面说，还描述了导致血脑屏障模型系统的微流控设备。6这样的设备在体外优化和加速药物开发时标中起着越来越重要的作用。

在最近的BioTM论文中，组织工程学也是一个经常讨论的主题，也与在工程学和再生医学界工作的大量研究人员保持一致。涵盖的组织工程主题包括水凝胶和脱细胞基质的工程以及组织特异性血管的产生。7-9讨论了各种形式的聚合物材料，包括复合材料，水凝胶和胶囊。10-12这些报告代表了一项伟大的研究活动，致力于了解聚合物材料的设计特征，聚合物-组织界面以及对其生物学功能的体内评估。

与一般文献趋势一致，最近的大量论文集中在纳米医学上。主题包括用于癌症的可翻译小鼠模型，13种新的纳米颗粒设计，14、15和可扩展的纳米颗粒合成方法。16，17，17翻译关注的报告，例如用于纳米医学的新型肿瘤模型和可扩展的合成方法，代表了对时间的特殊需求，我们期待着将来收到更多类似的翻译关注的纳米医学手稿。证明纳米颗粒新颖应用的研究在我们最近的出版物中也很突出，包括使用纳米颗粒改善防晒霜在皮肤上的停留18siRNA递送可用于淋巴瘤和伤口愈合。19，20关于医疗设备的论文包括人造胰腺的控制算法。21除了原始研究文章外，我们还发表了有关转化医学中当前活跃主题的评论，包括生物医学应用的离子液体，22纳米医学的临床前景，23和纳米晶体的转化状态。24 BioTM中的评论特别着重于报告该领域的翻译进展和障碍。

感谢我们的编辑委员会成员的大力支持。2020年，我们增加了六个新的编委会成员：Jennifer West（杜克大学），Xiaoyuan Chen（NIH），David Mooney（哈佛大学），Molly Stevens（伦敦帝国学院），Maria Jose Alonso（圣地亚哥·孔波斯特拉大学） （西班牙）和Andreas Lendlein（德国亥姆霍兹生物材料科学研究所）。我们期待董事会提供指导和远见。我们特别感谢董事会成员定期在BioTM中发表自己的研究成果。每期我们都有一名董事会成员。您可以在https://aiche.onlinelibrary.wiley.com/journal/hub/journal/23806761/homepage/editorialboardprofiles.html上阅读这些传记。

我们很高兴年轻一代的研究人员积极参与BioTM的推出和发展。支持的形式多种多样，包括特刊的客串编辑，手稿的提交和审稿。我们要特别感谢北卡罗来纳大学教堂山分校的Aaron Anselmo教授，他启动了我们的BioTM Buzz功能，该功能着重介绍了每一期的精选论文。在Twitter上关注BioTM_Buzz，以获取我们出版物的更新。

生物TM已出版了涉及多个主题的多个专题，包括医学中的纳米颗粒，核酸递送，反应材料和生物工程疗法，以及有关生物工程和转化医学会议以及国际工程会议（ECI）纳米技术的医学专题。我们还发行了特别刊物，以纪念该领域的两位杰出人物：Robert Langer和Nicholas Peppas。这些特殊问题由我们的热情赞助者（包括教授）编辑。Kaushal Rege，Kannan Rangaramajunam，Paolo Decuzzi，Zhen Gu，Kathryn Whitehead，Pankaj Karande，Josue Snitzman和Millicent Sullivan。我们对他们的奉献深表感谢。没有这些坚定不移的个人的积极参与，我们就不可能取得如此良好的开端。

在完成了5年的旅程之后，我期待着该期刊的下一阶段，它将包括每年出版物数量的增加，涵盖主题的扩大以及行业和国际作者在该期刊中的代表性增加。感谢大家对期刊的大力支持，并希望在未来几年内能继续提供支持。